Generic drugs were the preferred option over branded drug products in more than eight cases out of 10 in the French market through 2007, according to the health fund organization CNAM. The latter estimates that savings linked to the use of generics reached the 1.0 billion-euro ($1.55 billion) mark - a level comparable to 2006. However, the CNAM said this generics growth was likely to be less marked in the future because some copy drugs were being pushed aside in favor of newer and more costly branded medicines, especially in treatments for high cholesterol.
The level of market penetration of generics in 2007 was about 81.7% compared with just 53% in 2004 and the copy-cat sector tripled between 2002 and 2007. Generics reimbursement rose from about 500.0 million euros in 2002 to 1.2 billion euros in 2007, the CNAM notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze